Influence of physical activity on active surveillance discontinuation in men with low-risk prostate cancer

被引:5
|
作者
Papadopoulos, Efthymios [1 ,2 ]
Alibhai, Shabbir M. H. [2 ,3 ,4 ]
Tomlinson, George A. [3 ,4 ,6 ]
Matthew, Andrew G. [3 ,4 ]
Nesbitt, Michael [5 ]
Finelli, Antonio [3 ,5 ]
Trachtenberg, John [3 ,5 ]
Santa Mina, Daniel [1 ,2 ,3 ]
机构
[1] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Dept Support Care, Toronto, ON, Canada
[3] Univ Toronto, Fac Med, Toronto, ON, Canada
[4] Univ Hlth Network, Dept Med, Toronto, ON, Canada
[5] Princess Margaret Canc Ctr, Dept Surg Oncol, Div Urol, Toronto, ON, Canada
[6] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
关键词
Prostate cancer; Low-risk disease; Active surveillance; Physical activity; Treatment; EXERCISE; LIFE;
D O I
10.1007/s10552-019-01211-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Epidemiologic data suggest that high levels of physical activity (PA) may reduce the risk of disease progression in men with prostate cancer (PCa), but it is unknown whether PA can delay the requirement for definitive treatment for those on active surveillance (AS). We investigated the influence of PA post-diagnosis on AS discontinuation in men with low-risk disease. Methods The effect of PA on the time to AS discontinuation was assessed in 421 patients, of whom 107 underwent additional PCa treatment over a median of 2.5 years. Results Using Cox regression models, we found that PA was not significantly associated with time to curative treatment initiation. Prostate-specific antigen (PSA) most proximal to AS initiation (HR, 1.11; 95% CI 1.03 to 1.21) and the number of positive cores (HR, 1.34; 95% CI 1.12 to 1.61) at diagnosis were associated with a significantly increased risk of discontinuing AS. Conclusion Our findings suggest that PA during AS for PCa does not significantly influence time to curative treatment.
引用
收藏
页码:1009 / 1012
页数:4
相关论文
共 50 条
  • [21] Active surveillance preferred for low-risk prostate cancer
    Bagcchi, Sanjeet
    LANCET ONCOLOGY, 2015, 16 (08): : E384 - E384
  • [22] Is There a Role for Active Surveillance in Low-Risk Prostate Cancer?
    Augustin, Herbert
    Mayerhofer, Katrin
    Seles, Maximilian
    Pummer, Karl
    UROLOGIA INTERNATIONALIS, 2015, 95 (02) : 125 - 131
  • [23] Active Surveillance for Low-Risk Localized Prostate Cancer
    Large, Michael C.
    Eggener, Scott E.
    ONCOLOGY-NEW YORK, 2009, 23 (11): : 974 - 979
  • [24] Dutasteride and active surveillance of low-risk prostate cancer
    Fleshner, Neil E.
    LANCET, 2012, 379 (9826): : 1590 - 1590
  • [25] Active surveillance for low-risk prostate cancer: an update
    Lawrentschuk, Nathan
    Klotz, Laurence
    NATURE REVIEWS UROLOGY, 2011, 8 (06) : 312 - 320
  • [26] Active surveillance for low-risk prostate cancer: an update
    Nathan Lawrentschuk
    Laurence Klotz
    Nature Reviews Urology, 2011, 8 : 312 - 320
  • [27] Active Surveillance for Low-Risk Prostate Cancer Reply
    Lellig, Katja
    Buchner, Alexander
    Stief, Christian
    UROLOGE, 2015, 54 (06): : 870 - 870
  • [28] Factors That Influence Patient Enrollment in Active Surveillance for Low-risk Prostate Cancer
    Gorin, Michael A.
    Soloway, Cynthia T.
    Eldefrawy, Ahmed
    Soloway, Mark S.
    UROLOGY, 2011, 77 (03) : 588 - 591
  • [29] HEALTH LITERACY, ANXIETY, AND RISK OF HOSPITALIZATION IN MEN ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER
    Rogers, James
    Cullen, Brittany D.
    Epling, Joel
    Sartor, Oliver
    Silberstein, Jonathan
    Feibus, Allison
    Hoerger, Michael
    ANNALS OF BEHAVIORAL MEDICINE, 2018, 52 : S231 - S231
  • [30] Active surveillance versus nonradical treatment for low-risk men with prostate cancer: a review
    Perera, Sachin
    McDonald, Jodie
    Williams, Isabella
    O'Brien, Jonathan
    Murphy, Declan
    Lawrentschuk, Nathan
    PROSTATE INTERNATIONAL, 2022, 10 (03) : 117 - 122